Stay updated on Xospata Safety in Relapsed AML Clinical Trial

Sign up to get notified when there's something new on the Xospata Safety in Relapsed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Xospata Safety in Relapsed AML Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The displayed site revision changed from v3.7.2 to v3.8.0, with no change to the study record content.
    Difference
    0.1%
    Check dated 2026-11-01T15:34:18.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    An NIH notice announces a terminology transition, saying federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).
    Difference
    0.4%
    Check dated 2026-10-25T15:24:22.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T22:06:46.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, with no study-record content change indicated.
    Difference
    0.1%
    Check dated 2026-10-11T22:00:39.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    The revision history shows a new version label Revision: v3.7.0 added and the previous Revision: v3.6.6 removed, indicating the study record has been updated to a newer version.
    Difference
    0.1%
    Check dated 2026-09-20T19:44:14.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    The history now shows a new Revision: v3.6.6. It also removes Revision: v3.6.5, signaling a small platform update to the study history page.
    Difference
    0.1%
    Check dated 2026-08-30T06:49:07.000Z thumbnail image

Stay in the know with updates to Xospata Safety in Relapsed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Xospata Safety in Relapsed AML Clinical Trial page.